---

Secuencia óptima del tratamiento del CCRm: ¿Cuál es el papel del panitumumab?.

1

Advances in the treatment of mCRC

2

ESMO guidelines: mCRC treatment

3

The importance of 1st-line treatment choice in mCRC

4

Is there a treatment of choice in first-line of treatment in mCRC?

5

Número de diapositiva 6

6

Número de diapositiva 7

7

Meta-analysis of 1st-line anti-EGFR vs anti-VEGF in wtRAS mCRC

8

Response Rate

9

Disease Free Survival

10

Overall Survival

11

ESMO guidelines: mCRC treatment

12

Considerations for sequencing anti-EGFRvs anti-VEGF mAb therapy in mCRC

13

PEAK: ETS, DoR, TTR and DpR (RASwt, final analysis)

14

PEAK, PRIME, PLANET: Impact of ETS and DoR on survival

15

PEAK, PRIME, PLANET: Impact of ETS and DoR on survival

16

Considerations for sequencing anti-EGFRvs anti-VEGF mAb therapy in mCRC

17

Anti-EGFR-resistant cells may remain sensitive toanti-VEGF mAb therapy

18

Reduced activity of EGFR targeting antibodies following exposure toanti-VEGF mAb therapy

19

PRIME Post-progression anti-VEGF therapy (post-hoc analysis)

20

PRIME: OS by post-progression anti-VEGF therapy (wt RAS)

21

PRIME: OS by post-progression anti-VEGF therapy (wt RAS)

22

Impact of Sequence of Biologic Therapies on OS in wtRAS CRC: An Exploratory, Retrospective Pooled Analysis (PEAK, PRIME, 181)

23

Número de diapositiva 27

24

Número de diapositiva 28

25

Número de diapositiva 29

26

COMETS: Efficacy results

27

Does Bevacizumab impact antiEGFR efficacy in wtRAS mCRC?

28

Does Bevacizumab impact antiEGFR efficacy in wtRAS mCRC?

29

Planned Phase 3 study Biological sequencing

30

Conclusiones

31